Know Cancer

or
forgot password

A Pilot Study to Evaluate the Safety of Subcutaneous Alemtuzumab (MabCampath, Campath) in Patients With B-Cell Chronic Lymphocytic Leukemia


Phase 2
18 Years
80 Years
Not Enrolling
Both
B-CLL

Thank you

Trial Information

A Pilot Study to Evaluate the Safety of Subcutaneous Alemtuzumab (MabCampath, Campath) in Patients With B-Cell Chronic Lymphocytic Leukemia


Inclusion Criteria:



- B-CLL that has failed fludarabine

Exclusion Criteria:

- Performance status grade 3

Type of Study:

Interventional

Study Design:

Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment

Principal Investigator

Anders C Osterborg, Professor

Investigator Role:

Principal Investigator

Investigator Affiliation:

Dept. of Hematology, Karolinska University Hospital

Authority:

Sweden: Medical Products Agency

Study ID:

CAM219

NCT ID:

NCT00162851

Start Date:

April 2003

Completion Date:

July 2006

Related Keywords:

  • B-CLL
  • Leukemia
  • Leukemia, Lymphocytic, Chronic, B-Cell
  • Leukemia, Lymphoid

Name

Location